A Phase 3 study (CheckMate 214) evaluating nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma reached its primary completion on 2017-06-26. The combination therapy demonstrated an objective response rate of 41.6% compared to 26.5% for sunitinib in intermediate/poor risk participants. Overall survival for any risk participants was 52.70 months with the combination versus 37.75 months for sunitinib.
Background
The study investigated nivolumab combined with ipilimumab as a treatment for patients with previously untreated advanced or metastatic renal cell carcinoma. This combination was compared against sunitinib monotherapy, a standard treatment, to assess its efficacy in this patient population.
Trial design
The Phase 3 study (NCT02231749), known as CheckMate 214, enrolled 1096 participants with previously untreated advanced or metastatic renal cell carcinoma. The trial compared the efficacy of nivolumab combined with ipilimumab against sunitinib monotherapy. Key objectives included evaluating objective response rate, progression-free survival, and overall survival.
Key results
The trial reported several key outcome measurements, highlighting the efficacy of the combination therapy:
- Objective Response Rate (ORR) in Intermediate/Poor Risk Participants: The nivolumab + ipilimumab arm achieved an ORR of 41.6%, compared to 26.5% for the sunitinib arm.
- Progression-Free Survival (PFS) in Intermediate/Poor-Risk Participants: Median PFS was 11.56 months for nivolumab + ipilimumab versus 8.38 months for sunitinib.
- Overall Survival (OS) in Any Risk Participants: Median OS was 52.70 months for nivolumab + ipilimumab compared to 37.75 months for sunitinib.
Statistical analyses further supported these findings, including a stratified difference of 16.0 (95.0% CI: 9.8, 22.2) with a p-value of 0.0001, and a Hazard Ratio (HR) of 0.63 (99.8% CI: 0.44, 0.89) with a p-value of 0.0001.
What this means
The primary completion of the CheckMate 214 trial demonstrated that the combination of nivolumab and ipilimumab offers a significant therapeutic advantage over sunitinib monotherapy for patients with previously untreated advanced or metastatic renal cell carcinoma. The superior objective response rates and longer progression-free survival observed in intermediate/poor risk participants, alongside improved overall survival in the overall study population, highlight the potential of this immunotherapy combination as a new standard of care.
Source
The information regarding this trial's primary completion and results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT02231749, titled "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)", were posted on 2017-06-26 on clinicaltrials.gov.